Cargando…
Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn’s disease and ulcerative colitis in the United States
BACKGROUND: The purpose of this analysis was to assess the frequency of inadequate response over 1 year from advanced therapy initiation among patients with Crohn’s disease (CD) or ulcerative colitis (UC) in the United States using a claims-based algorithm. Factors associated with inadequate respons...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996947/ https://www.ncbi.nlm.nih.gov/pubmed/36894911 http://dx.doi.org/10.1186/s12876-023-02675-w |
_version_ | 1784903157954904064 |
---|---|
author | Gibble, Theresa Hunter Naegeli, April N. Grabner, Michael Isenberg, Keith Shan, Mingyang Teng, Chia-Chen Curtis, Jeffrey R. |
author_facet | Gibble, Theresa Hunter Naegeli, April N. Grabner, Michael Isenberg, Keith Shan, Mingyang Teng, Chia-Chen Curtis, Jeffrey R. |
author_sort | Gibble, Theresa Hunter |
collection | PubMed |
description | BACKGROUND: The purpose of this analysis was to assess the frequency of inadequate response over 1 year from advanced therapy initiation among patients with Crohn’s disease (CD) or ulcerative colitis (UC) in the United States using a claims-based algorithm. Factors associated with inadequate response were also analyzed. METHODS: This study utilized claims data of adult patients from the HealthCore Integrated Research Database (HIRD(®)) from January 01, 2016 to August 31, 2019. Advanced therapies used in this study were tumor necrosis factor inhibitors (TNFi) and non-TNFi biologics. Inadequate response to an advanced therapy was identified using a claims-based algorithm. The inadequate response criteria included adherence, switching to/added a new treatment, addition of a new conventional synthetic immunomodulator or conventional disease-modifying drugs, increase in dose/frequency of advanced therapy initiation, and use of a new pain medication, or surgery. Factors influencing inadequate responders were assessed using multivariable logistic regression. RESULTS: A total of 2437 patients with CD and 1692 patients with UC were included in this analysis. In patients with CD (mean age: 41 years; female: 53%), 81% had initiated TNFi, and 62% had inadequate response. In patients with UC (mean age: 42 years; female: 48%), 78% had initiated a TNFi, and 63% had an inadequate response. In both patients with CD and UC, inadequate response was associated with low adherence (CD: 41%; UC: 42%). Inadequate responders were more likely to be prescribed a TNFi (for CD: odds ratio [OR] = 1.94; p < 0.001; for UC: OR = 2.76; p < 0.0001). CONCLUSION: More than 60% of patients with CD or UC had an inadequate response to their index advanced therapy within 1 year after initiation, mostly driven by low adherence. This modified claims-based algorithm for CD and UC appears useful to classify inadequate responders in health plan claims data. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-023-02675-w. |
format | Online Article Text |
id | pubmed-9996947 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-99969472023-03-10 Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn’s disease and ulcerative colitis in the United States Gibble, Theresa Hunter Naegeli, April N. Grabner, Michael Isenberg, Keith Shan, Mingyang Teng, Chia-Chen Curtis, Jeffrey R. BMC Gastroenterol Research BACKGROUND: The purpose of this analysis was to assess the frequency of inadequate response over 1 year from advanced therapy initiation among patients with Crohn’s disease (CD) or ulcerative colitis (UC) in the United States using a claims-based algorithm. Factors associated with inadequate response were also analyzed. METHODS: This study utilized claims data of adult patients from the HealthCore Integrated Research Database (HIRD(®)) from January 01, 2016 to August 31, 2019. Advanced therapies used in this study were tumor necrosis factor inhibitors (TNFi) and non-TNFi biologics. Inadequate response to an advanced therapy was identified using a claims-based algorithm. The inadequate response criteria included adherence, switching to/added a new treatment, addition of a new conventional synthetic immunomodulator or conventional disease-modifying drugs, increase in dose/frequency of advanced therapy initiation, and use of a new pain medication, or surgery. Factors influencing inadequate responders were assessed using multivariable logistic regression. RESULTS: A total of 2437 patients with CD and 1692 patients with UC were included in this analysis. In patients with CD (mean age: 41 years; female: 53%), 81% had initiated TNFi, and 62% had inadequate response. In patients with UC (mean age: 42 years; female: 48%), 78% had initiated a TNFi, and 63% had an inadequate response. In both patients with CD and UC, inadequate response was associated with low adherence (CD: 41%; UC: 42%). Inadequate responders were more likely to be prescribed a TNFi (for CD: odds ratio [OR] = 1.94; p < 0.001; for UC: OR = 2.76; p < 0.0001). CONCLUSION: More than 60% of patients with CD or UC had an inadequate response to their index advanced therapy within 1 year after initiation, mostly driven by low adherence. This modified claims-based algorithm for CD and UC appears useful to classify inadequate responders in health plan claims data. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-023-02675-w. BioMed Central 2023-03-09 /pmc/articles/PMC9996947/ /pubmed/36894911 http://dx.doi.org/10.1186/s12876-023-02675-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Gibble, Theresa Hunter Naegeli, April N. Grabner, Michael Isenberg, Keith Shan, Mingyang Teng, Chia-Chen Curtis, Jeffrey R. Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn’s disease and ulcerative colitis in the United States |
title | Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn’s disease and ulcerative colitis in the United States |
title_full | Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn’s disease and ulcerative colitis in the United States |
title_fullStr | Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn’s disease and ulcerative colitis in the United States |
title_full_unstemmed | Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn’s disease and ulcerative colitis in the United States |
title_short | Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn’s disease and ulcerative colitis in the United States |
title_sort | identification of inadequate responders to advanced therapy among commercially-insured adult patients with crohn’s disease and ulcerative colitis in the united states |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996947/ https://www.ncbi.nlm.nih.gov/pubmed/36894911 http://dx.doi.org/10.1186/s12876-023-02675-w |
work_keys_str_mv | AT gibbletheresahunter identificationofinadequateresponderstoadvancedtherapyamongcommerciallyinsuredadultpatientswithcrohnsdiseaseandulcerativecolitisintheunitedstates AT naegeliapriln identificationofinadequateresponderstoadvancedtherapyamongcommerciallyinsuredadultpatientswithcrohnsdiseaseandulcerativecolitisintheunitedstates AT grabnermichael identificationofinadequateresponderstoadvancedtherapyamongcommerciallyinsuredadultpatientswithcrohnsdiseaseandulcerativecolitisintheunitedstates AT isenbergkeith identificationofinadequateresponderstoadvancedtherapyamongcommerciallyinsuredadultpatientswithcrohnsdiseaseandulcerativecolitisintheunitedstates AT shanmingyang identificationofinadequateresponderstoadvancedtherapyamongcommerciallyinsuredadultpatientswithcrohnsdiseaseandulcerativecolitisintheunitedstates AT tengchiachen identificationofinadequateresponderstoadvancedtherapyamongcommerciallyinsuredadultpatientswithcrohnsdiseaseandulcerativecolitisintheunitedstates AT curtisjeffreyr identificationofinadequateresponderstoadvancedtherapyamongcommerciallyinsuredadultpatientswithcrohnsdiseaseandulcerativecolitisintheunitedstates |